drugset / Trial / NCT05107219
GCC Agonist Signal in the Small Intestine
Phase 1
Completed
43 enrolled
University of Wisconsin, Madison
National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on a certain chemical found in the tissue collected from small intestine and how they compare.
Timeline
- Start
- 2022-11-30
- Primary completion
- 2026-02-06
- Completion
- 2026-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linaclotide | Peptide | 145 ug | Oral |
| Subject | Plecanatide | Peptide | 3 mg | Oral |